DF/HCC Cancer Proteomics Center
The Core provides all of the tools of modern functional proteomics and metabolomics. Equipped with State-of-the-Art technologies for proteomics and metabolomics; protein profiling, protein identification, protein and peptide fractionation, post-translational modification analysis, metabolite profiling, and quantitative proteomics. Personalized experimental design consultation, comprehensive individualized bioinformatics, and systems biology support.
On the heels of the genomic revolution, proteomics and metabolomics are at the forefront of cancer research, aiming to provide a thorough understanding of complex disease processes, including cancer. With the aid of knowledge-based analytical fields such as bioinformatics, proteomic and metabolomic technologies (e.g., mass spectrometry, HPLC fractionation) provide the means to compare profiles in normal and pathological tissues and correlate them with biological and clinical function, identify temporal patterns of protein and metabolite expression and post-translational modifications, and define the function and interactions of proteins and metabolites.
The Cancer Proteomics Core provides investigators involved in clinical and translational studies with access to comprehensive high sensitivity, high resolution, and high throughput proteomics and metabolomics services. There is particular emphasis on clinical sample analysis and in-depth scientific consultation in proteomics, metabolomics, and data analysis. Basic researchers who are exploring signaling pathways and other aspects of cancer biology are also able to receive access to sophisticated proteomic and metabolomic services and expert consultation. The facility pushes the limits of proteomics and metabolomics technologies and specializes in cancer projects utilizing blood, urine, cerebrospinal fluid, saliva, cyst fluids, interstitial fluids, cell and tissue extracts to: gain insight into cancer processes; discover new biomarkers for early detection, diagnosis, prognosis, and outcome prediction; study population effects; manage clinical trials; evaluate drug efficacy and toxicity; stratify patients; identify tumor antigens; and accelerate drug development. A unique aspect of the Cancer Proteomics Core has been its expertise in basic, translational, and clinical cancer research, as well as in proteomics, metabolomics, systems biology, and bioinformatics. The staff is able to provide expertise in all aspects of cancer research, as well as study design and data analysis and understands the complexities and challenges of proteomics projects.
Leadership and Staff
Co-Director: John Asara, PhD
Bioinformatics Director: Manoj Bhasin, PhD
Research Associate: Bob Choy, PhD
PUBLICATION ACKNOWLEDGEMENT: If research supported by this core facility results in publication, please acknowledge this support by including the following in your publication(s):
We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Cancer Proteomics Core, which provided __________ service. Dana-Farber/Harvard Cancer Center is supported in part by a NCI Cancer Center Support Grant # NIH 5 P30 CA06516.